GlassScriptPhysician profile
Bradley J Phillips
NPI 1104800143
$14,822.35
in general payments reported to CMS, 2019-2025
32 companies · $1,768 in 2025
The $1,768 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,907 · 2020: $799 · 2021: $1,155 · 2022: $1,807 · 2023: $1,299 · 2024: $5,088 · 2025: $1,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,902 · Travel and Lodging: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,902.17 |
| Travel and Lodging | $1,252.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $3,930.73 | 2022-2025 | Stellaris Elite, Envista Aspire Iol, Teneo |
| Alcon Vision LLC | $2,502.54 | 2019-2025 | Argos, Tryptyr, Ngenuity |
| Johnson & Johnson Surgical Vision, INC. | $1,198.62 | 2019-2021 | |
| Allergan, INC. | $1,024.68 | 2019-2022 | |
| Sight Sciences, INC. | $901.88 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $585.52 | 2019-2021 | |
| Glaukos Corporation | $526.34 | 2019-2024 | Idose |
| Novartis Pharmaceuticals Corporation | $512.23 | 2019-2023 | |
| Abbvie INC. | $486.53 | 2022-2025 | |
| Biotissue Holdings INC. | $481.34 | 2024 | |
| Carl Zeiss Meditec USA, INC. | $429.04 | 2024 | Iolmaster 700 |
| Horizon Therapeutics Plc | $292.47 | 2020-2023 | Tepezza |
| New World Medical,INC. | $262.33 | 2019 | |
| Oyster Point Pharma, INC. | $227.33 | 2022-2025 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $205.21 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $174.13 | 2019-2024 | Cequa |
| Genentech USA, INC. | $152.82 | 2024 | Vabysmo |
| Dompe US, INC. | $150.78 | 2022-2025 | Oxervate |
| Catalyst Pharmaceuticals, INC. | $127.05 | 2025 | |
| Rayner Intraocular Lenses Limited | $105.11 | 2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Mallinckrodt Hospital Products INC. | $99.29 | 2021-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $97.99 | 2025 | Eylea Hd |
| Ivantis, INC | $71.36 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $68.71 | 2024 | Xdemvy |
| Amgen INC. | $56.82 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $49.30 | 2024 | Vevye |
| Astellas Pharma US INC | $19.18 | 2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.85 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.56 | 2021 | |
| Travere Therapeutics, INC. | $17.99 | 2019 | |
| Argenx US, INC. | $16.44 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Shire North American Group INC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.